Use of dipyridamole is associated with lower risk of lymphoid neoplasms: a propensity score‐matched cohort study. (23rd September 2021)

• Record Type: Journal Article
• Authors: Huang, Wuqing; Sundquist, Kristina; Sundquist, Jan; Ji, Jianguang
• Is Part Of: British journal of haematology. Volume 196:Number 3(2022)
• Page Start: 690
• Page End: 699
• Publication Date: 2021-09-23
• Subjects: dipyridamole -- lymphoid neoplasms -- cohort study -- drug repurposing; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.17851
• Languages: English
• ISSNs: 0007-1048

Abstract

Summary: The anti‐cancer potential of dipyridamole has been suggested from experiments, but evidence from population‐based studies is still lacking. We aimed to explore if dipyridamole use was related to a lower risk of lymphoid neoplasms. We identified individuals with prescription of aspirin after diagnosis of ischaemic cerebrovascular disease since 2006 by linking several Swedish registers. In these aspirin users, those with dipyridamole prescription were further identified as the study group and patients without dipyridamole were randomly selected as reference group with 1:1 ratio using a propensity score‐matching approach. After a median of 6·67 years of follow‐up, a total of 46 patients with dipyridamole use developed lymphoid neoplasms with an incidence rate of 0·49 per 1 000 person‐years, while the rate in the matched group was 0·74 per 1 000 person‐years. As compared to non‐users, dipyridamole users were associated with a significantly decreased risk of lymphoid neoplasms [hazard ratio (HR) = 0·65; 95% confidence interval (CI) = 0·43‐0·98]. Specifically, the reduced risk was observed for non‐Hodgkin lymphomas (HR = 0·64; 95% CI = 0·42‐0·94), especially B‐cell lymphomas (HR = 0·56; 95% CI = 0·35‐0·88). Dipyridamole use was related to a lower risk of lymphoid neoplasms, indicating a clinical potential of dipyridamole to be an adjunct anti‐tumour agent against lymphoid neoplasms.